3.29
+0.01(+0.30%)
Currency In USD
| Previous Close | 3.28 |
| Open | 3.23 |
| Day High | 3.4 |
| Day Low | 3.2 |
| 52-Week High | 11.46 |
| 52-Week Low | 1.07 |
| Volume | 1.31M |
| Average Volume | 7.28M |
| Market Cap | 314.85M |
| PE | -3.54 |
| EPS | -0.93 |
| Moving Average 50 Days | 3.57 |
| Moving Average 200 Days | 5.93 |
| Change | 0.01 |
If you invested $1000 in Rezolute, Inc. (RZLT) 10 years ago, it would be worth $65.8 as of February 21, 2026 at a share price of $3.29. Whereas If you bought $1000 worth of Rezolute, Inc. (RZLT) shares 5 years ago, it would be worth $271.9 as of February 21, 2026 at a share price of $3.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
GlobeNewswire Inc.
Feb 12, 2026 9:05 PM GMT
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported fina
Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 04, 2026 12:00 PM GMT
REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced tha
Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
GlobeNewswire Inc.
Jan 07, 2026 12:00 PM GMT
Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to meet with FDA to align on path forward for congenital HI REDWOOD CITY, Calif., Jan. 07, 2026